NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
Clinical Trials
9 trialsNCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT01870505 2024-12-09
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT01381874 2019-04-11
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT02248571 2017-11-13
IMPROVE
iOMEDICO AG
Phase 4 Completed